Literature DB >> 8855837

Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium.

M K Tennant1, J B Thrasher, P A Twomey, R H Drivdahl, R S Birnbaum, S R Plymate.   

Abstract

Insulin-like growth factors (IGFs) and the type 1 IGF receptor (IGF-R) are involved in normal growth and development of the human prostate. Changes in levels of IGF-R and IGFs have been shown for several malignancies. Immunohistochemistry and in situ hybridization were performed to compare the expression of IGF-R and IGF-II in vivo in prostate tissue containing benign epithelium, high grade prostate intraepithelial neoplasia (PIN), and adenocarcinoma. Messenger ribonucleic acid (mRNA) hybridization signals and immunoreactivity for IGF-R were localized primarily to epithelial cells, with less signal in stroma. IGF-R mRNA was significantly decreased by 42% in PIN and 35% in cancer cells compared to that in benign epithelium (P < 0.0001). IGF-R immunostaining was significantly decreased by 32% in PIN and by 42% in malignant epithelium compared to that in benign epithelium (P < 0.004). IGF-II mRNA was also localized primarily to epithelial cells. IGF-II mRNA was significantly increased by 30% in adenocarcinoma compared to that in benign epithelium (P < 0.03). Immunoreactivity for IGF-II was localized to both stroma and epithelium. Protein levels for IGF-II were not significantly increased in cancer cells compared to those in benign epithelium. The decrease in the type 1 IGF receptor and increase in IGF-II mRNA may affect prostate cancer proliferation and differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855837     DOI: 10.1210/jcem.81.10.8855837

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; D De León
Journal:  Growth Horm IGF Res       Date:  2010-03-27       Impact factor: 2.372

2.  Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene.

Authors:  Hagit Schayek; Itay Bentov; Shihua Sun; Stephen R Plymate; Haim Werner
Journal:  Exp Cell Res       Date:  2010-03-23       Impact factor: 3.905

3.  Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis.

Authors:  S S Plymate; V L Bae; L Maddison; L S Quinn; J L Ware
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

Review 4.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

5.  Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment.

Authors:  Petra Massoner; Michael Ladurner Rennau; Isabel Heidegger; Anita Kloss-Brandstätter; Monika Summerer; Eva Reichhart; Georg Schäfer; Helmut Klocker
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

6.  Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium.

Authors:  Elin Richardsen; Tanja Ukkonen; Tone Bjørnsen; Elin Mortensen; Lars Egevad; Christer Busch
Journal:  Virchows Arch       Date:  2003-04-01       Impact factor: 4.064

7.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

8.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

Review 9.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  The insulin-like growth factor system and its receptors: A potential novel anticancer target.

Authors:  Colin R Lindsay; Tr Jeffry Evans
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.